The Gouty Arthritis (Gout) drugs in development market research report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Gouty Arthritis (Gout). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Gouty Arthritis (Gout) and features dormant and discontinued products.
GlobalData tracks 67 drugs in development for Gouty Arthritis (Gout) by 62 companies/universities/institutes. The top development phase for Gouty Arthritis (Gout) is preclinical with 22 drugs in that stage. The Gouty Arthritis (Gout) pipeline has 63 drugs in development by companies and four by universities/ institutes. Some of the companies in the Gouty Arthritis (Gout) pipeline products market are: Tonghua Dongbao Pharmaceutical, Jiangsu Atom Bioscience and Pharmaceutical and Jiangsu Hengrui Medicine.
The key targets in the Gouty Arthritis (Gout) pipeline products market include Solute Carrier Family 22 Member 12, Xanthine Dehydrogenase/Oxidase, and Uric Acid.
The key mechanisms of action in the Gouty Arthritis (Gout) pipeline product include Solute Carrier Family 22 Member 12 Inhibitor with 17 drugs in Pre-Registration. The Gouty Arthritis (Gout) pipeline products include ten routes of administration with the top ROA being Oral and nine key molecule types in the Gouty Arthritis (Gout) pipeline products market including Small Molecule, and Recombinant Enzyme.
Gouty Arthritis (Gout) overview
Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in the blood and causes inflammation in the joints. Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area, and joint redness. Risk factors include obesity, high alcohol intake, injury to a joint, long-standing kidney disease, and high intake of foods rich in purines.
For a complete picture of Gouty Arthritis (Gout)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
